AXT Inc. Form 10-Q Summary
Business context and reporting period
AXT develops and manufactures compound and single-element semiconductor substrates, including gallium arsenide (GaAs), indium phosphide (InP) and germanium wafers, plus related raw materials. All manufacturing occurs in China through subsidiaries and joint ventures. The filing covers the unaudited three months ended March 31, 2015, compared with the three months ended March 31, 2014.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | $20.064 million | $19.345 million | +3.7% |
| Gross profit | $4.749 million | $2.718 million | +74.7% |
| Gross margin | 23.7% | 14.1% | +9.6 percentage points |
| Operating loss | $1.743 million | $2.400 million | Improved by $657,000 |
| Net loss | $899,000 | $1.835 million | Improved by $936,000 |
| Loss attributable to AXT | $1.024 million | $2.040 million | Improved by $1.016 million |
| Loss per common share | $0.03 | $0.06 | Improved |
| Net cash used in operations | $349,000 | $387,000 | Use decreased by $38,000 |
- SG&A increased 52.8% to $5.251 million, primarily due to approximately $1.2 million of professional fees related to the related-party investigation and higher personnel costs.
- Research and development expense increased 60.1% to $1.241 million.
- Other income increased to $633,000, primarily from a $367,000 gain on sales of IntelliEPI shares and $180,000 of foreign-exchange gains.
- Cash and cash equivalents were $33.285 million at March 31, 2015. Total cash, cash equivalents and investments were $47.487 million.
- Investing activities provided $5.299 million, principally from $10.277 million of investment sales and maturities, partly offset by $4.304 million of investment purchases and $676,000 of capital expenditures.
- Inventory was $39.475 million, including an excess and obsolete inventory reserve of $11.4 million.
- Total liabilities were $16.877 million. The filing reports no outstanding borrowings; the unused $10 million credit facility was terminated in January 2015.
- AXT repurchased approximately 230,000 shares for $617,000 during the quarter, leaving approximately $4.4 million available under its $5 million repurchase authorization.
Material changes versus the prior comparable period
- Revenue growth was driven by stronger InP demand, particularly for fiber-optic lasers and data connectivity, and higher raw-material sales. These gains were partly offset by lower demand for other substrates, especially germanium.
- Geographic revenue shifted materially: North America increased 95% to $3.472 million, while Europe declined 25% to $4.943 million and China declined 21% to $3.297 million.
- Gross margin improved substantially because of product mix and ongoing cost-saving initiatives.
- The first quarter of 2014 included a $907,000 restructuring charge related to a reduction of approximately 93 positions at Tongmei; no restructuring charge was recorded in Q1 2015.
- Equity earnings from unconsolidated joint ventures declined to $200,000 from $487,000, reflecting lower investee profitability.
- Top-five customers represented 35% of revenue versus 39% in the prior-year quarter; no individual customer exceeded 10% of revenue in either period.
Outlook, commentary, risks and unusual items
- Management stated that existing cash and investments should meet operating and capital needs for the next 12 months, although weaker sales could accelerate cash use and require additional capital.
- Management expected SG&A to decrease in Q2 2015 because the related-party investigation had concluded and additional professional fees were not anticipated.
- On February 23, 2015, the Audit Committee disclosed an investigation into potential historical related-party transactions involving Davis Zhang. The investigation found no intentional misconduct, improper benefit or financial-statement inaccuracies, but identified previously undisclosed transactions. Approximately $1.8 million of professional fees were incurred.
- Davis Zhang resigned as President, China Operations, effective May 15, 2015.
- China added gallium arsenide to its hazardous-substances list and required a permit to continue manufacturing GaAs wafers. As of the filing date, the permit application remained under review. A forced production halt could materially reduce revenue and profits and affect several hundred employees.
- Key ongoing risks include semiconductor cyclicality, declining average selling prices, competition from silicon-based alternatives and other GaAs suppliers, manufacturing yield and quality issues, customer concentration, dependence on China-based operations and suppliers, foreign-exchange volatility, environmental and safety compliance, and potential inventory impairment.
- Contractual obligations totaled $3.015 million, consisting of $690,000 of operating leases and $2.325 million under a royalty agreement. The company reported no off-balance-sheet financing arrangements and no purchase orders subject to cancellation penalties.
Important facts for investors to verify
- Whether AXT obtained the required Chinese permit and maintained uninterrupted GaAs wafer production after May 2015.
- Whether the improvement in gross margin is sustainable after the favorable product mix and cost-saving effects.
- The normalization of SG&A following the completed related-party investigation and whether further investigation-related costs arise.
- Inventory demand, reserves and aging, particularly against the $39.5 million inventory balance and $11.4 million reserve.
- Operating cash-flow performance, liquidity held in China, and the tax or other restrictions affecting repatriation of approximately $13.6 million of foreign-held cash and investments.
- Progress following the resignation of the President of China Operations and any additional related-party disclosures or governance actions.